Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
127.31
+2.95 (+2.37%)
Official Closing Price
Updated: 7:00 PM EST, Nov 21, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
European Stocks Soar as Strong Earnings Quell 'AI Bubble' Fears
November 20, 2025
European equity markets have experienced a significant resurgence around November 20, 2025, with major indices climbing as robust company results, particularly from the technology sector, have...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Supply Chain
Novartis Projects Faster Growth Through 2030 After Raising Drug Forecasts
↗
November 20, 2025
Novartis raises long-term sales targets, boosts outlook for key medicines and outlines a pipeline strategy driving growth through 2030.
Via
Benzinga
Novartis Stock Softens Premarket Even As It Raises 2030 Outlook, Sales Guidance For Two Key Cancer Drugs
↗
November 20, 2025
Via
Stocktwits
Big Pharma Layoff Wave Extends Into Next Year: UNH, Merck, BMS, Novartis File New WARN Notices
↗
November 20, 2025
Via
Stocktwits
Topics
Workforce
Novartis Opens New Manufacturing Facility In California In Bid To Increase US Presence
↗
November 10, 2025
Via
Stocktwits
Is the Market Bullish or Bearish on Novartis AG?
↗
November 18, 2025
Via
Benzinga
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring
↗
November 17, 2025
AI breakthroughs in pharma are pushing Eli Lilly and healthcare stocks higher—and may soon reshape how we fight cancer.
Via
Benzinga
Topics
Artificial Intelligence
Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Strong Case for Dividend Investors
↗
November 17, 2025
Novartis (NVS) offers a strong 3.31% dividend yield with a history of reliable payouts and growth, backed by excellent profitability and financial health.
Via
Chartmill
Trump Unveils $200 Billion Trade Deal With Switzerland And Liechtenstein To Cull $38.5 Billion US Goods Deficit By 2028
↗
November 15, 2025
President Donald Trump announced a framework for a trade deal with Switzerland and Liechtenstein on Friday.
Via
Benzinga
Topics
Government
AI Revolutionizes Drug Shelf-Life: Optimized Stability Models Promise Safer, More Effective Medicines
November 14, 2025
The pharmaceutical industry is on the cusp of a profound transformation, driven by the integration of data science and Artificial Intelligence (AI) into drug formulation stability models. This...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
Product Recall
Biopharma Boom: M&A Frenzy, AI Revolution, and GLP-1 Gold Rush Drive Robust Growth in 2025
November 14, 2025
The pharmaceutical and biotechnology sectors are experiencing a period of significant dynamism and robust growth as of November 2025, fueled by a confluence of scientific advancements, a resurgence in...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Intellectual Property
AI Revolutionizes Cardiovascular Clinical Trials: A Leap Towards Cheaper, Faster Drug Development
November 13, 2025
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This...
Via
TokenRing AI
Topics
Artificial Intelligence
Novartis' Investigational Medicine Shows Potent Activity Against Drug-Resistant Malaria Strains
↗
November 13, 2025
Novartis' GanLum met key Phase 3 goals, showing strong efficacy and safety in malaria patients, including against resistant parasite strains.
Via
Benzinga
Eledon Pharmaceuticals Stock Plunges Following $50 Million Public Offering
November 12, 2025
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the...
Via
MarketMinute
Topics
Initial Public Offering
Intellectual Property
Regulatory Compliance
AI’s Next Frontier: Key Stocks to Watch Amidst Market Shifts and Technological Leaps
November 10, 2025
The artificial intelligence (AI) sector is currently navigating a period of unprecedented dynamism, characterized by explosive technological advancements, massive capital inflows, and a palpable...
Via
TokenRing AI
Topics
Artificial Intelligence
AI Achieves Atomic Precision in Antibody Design: A New Era for Drug Discovery Dawns
November 05, 2025
Seattle, WA – November 5, 2025 – In a monumental leap for biotechnology and artificial intelligence, Nobel Laureate David Baker’s lab at the University of Washington’s Institute for Protein Design...
Via
TokenRing AI
Topics
Artificial Intelligence
Intellectual Property
Celcuity Eyeing Cancer Treatment Riddle. Stock Flys 534% This Year.
↗
November 05, 2025
The company hopes to "solve a 20-year riddle" in cancer treatment. The journey has sent the biotech stock flying as much as 534%.
Via
Investor's Business Daily
AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential
November 04, 2025
The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...
Via
TokenRing AI
Topics
Artificial Intelligence
Terns Pharmaceuticals' Leukemia Drug Seen As Potential Disruptor In CML Treatment Landscape, Analyst Upgrades
↗
November 03, 2025
Terns Pharmaceuticals shares rise after TERN-701 shows a 75% response rate in the CML trial, and William Blair upgrades the stock to Outperform.
Via
Benzinga
iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally
↗
November 03, 2025
iShares Core MSCI EAFE ETF (IEFA) Focuses on Developed Markets While Vanguard FTSE All-World ex-US ETF (VEU) Looks Globally
Via
The Motley Fool
Topics
ETFs
Trump Offers Help To 'Dilbert' Creator's Cancer Fight
↗
November 03, 2025
Trump offers help to cancer-stricken Dilbert creator Scott Adams after he appeals for assistance on social media. Adams seeks access to Pluvicto treatment for metastatic prostate cancer.
Via
Benzinga
Topics
Government
The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)
↗
November 02, 2025
The Vanguard FTSE Developed Markets ETF (VEA) Offers Broader Diversification Than the SPDR Portfolio Developed World ex-US ETF (SPDW)
Via
The Motley Fool
Topics
ETFs
Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW
↗
November 02, 2025
Vanguard VEA ETF Boasts Broader Portfolio Than State Street's SPDR SPDW
Via
The Motley Fool
Topics
ETFs
AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio
November 01, 2025
The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...
Via
TokenRing AI
Topics
Animal Testing
Artificial Intelligence
Economy
The AI Imperative: Why Rapid Upskilling is Non-Negotiable for Pharma’s Future
October 31, 2025
The pharmaceutical sector stands at the precipice of a profound transformation, driven by the relentless march of artificial intelligence (AI) and other advanced technologies. As highlighted by...
Via
TokenRing AI
Topics
Artificial Intelligence
Economy
AI Revolutionizes Pharma: Smarter Excipients for Safer, More Potent Drugs
October 31, 2025
San Francisco, CA – October 31, 2025 – Artificial intelligence (AI) is ushering in a transformative era for the pharmaceutical industry, particularly in the often-overlooked yet critical domain of...
Via
TokenRing AI
Topics
Artificial Intelligence
Supply Chain
AI Revolutionizes Pharma R&D: A New Era of Accelerated Drug Discovery and Personalized Medicine
October 31, 2025
Artificial intelligence (AI) is ushering in a transformative era for pharmaceutical research and development (R&D), fundamentally reshaping how new medicines are discovered, developed, and brought to...
Via
TokenRing AI
Topics
Artificial Intelligence
Intellectual Property
AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future
October 31, 2025
The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...
Via
TokenRing AI
Topics
Animal Testing
Artificial Intelligence
Economy
Here's Why Avidity Biosciences Stock Soared This Week (There's More to the Deal Than You Might Think)
↗
October 31, 2025
Novartis is set to boost its developmental pipeline with this acquisition.
Via
The Motley Fool
Here's My Favorite Passive Income Investment
↗
October 31, 2025
International dividend stocks are finally having their moment after years of underperformance, and this single Vanguard fund captures the opportunity with rock-bottom fees.
Via
The Motley Fool
Topics
ETFs
< Previous
1
2
3
4
5
6
7
8
9
...
38
39
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today